Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma

Affiliations

• 1 Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada.
• 2 Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
• 3 Lady Davis Institute, Jewish General Hospital, Montréal, Canada.
• 4 Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada.
• 5 Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada; Manitoba Centre for Proteomics and Systems Biology, University of Manitoba, Winnipeg, Canada.
• 6 Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada.
• 7 Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada.
• 8 Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada. Electronic address: soniavictoria.delrincon@mcgill.ca.
• 9 Lady Davis Institute, Jewish General Hospital, Montréal, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Department of Oncology, McGill University, Montréal, Canada. Electronic address: michael.witcher@mcgill.ca.